Results 191 to 200 of about 74,284 (255)

NIR Ratiometric Fluorescent Antibody-Drug Conjugate for Metastatic Ovarian Cancer Theranostics and Treatment Response Monitoring. [PDF]

Adv Sci (Weinh)
Li C, Yu Z, Pu T, Wu Y, Wang G, Xie Y, Ying T, Yang Z, Shi Y.   +8 more
europepmc   +1 more source

From Payload‐First Toward Dual‐Mechanism Antibody–Drug Conjugates

Advanced Materials, EarlyView.
Conjugation converts potent antibodies into underexposed carriers. This perspective defines the antibody exposure deficit and maps a mechanism‐first design space from payload‐first to antibody‐first ADC architectures, integrating DAR, linker chemistry, and Fc engineering to guide rational design of constructs that balance targeted cytotoxicity with ...
Xavier Pivot, Sebastian Jung, Sébastien Harlepp, Alexandre Detappe   +3 more
wiley   +1 more source

Metal–Organic Framework‐Preserved Thermostable Microneedle Patch for Minimally Invasive Detection and Monitoring of Kidney Dysfunction

Advanced Materials, EarlyView.
By growing a conformal ZIF‐8 protective layer directly on antibody‐functionalized microneedles, this work converts a fragile biosensing interface into a thermostable diagnostic platform. The MOF@MN patch enables minimally invasive NGAL detection from dermal ISF while supporting cold‐chain‐independent storage and transport for decentralized kidney ...
Yixuan Wang, Ying Liu, Avishek Debnath, Chuang Li, Zheyu Wang, Gayathri Kondepati, Saketh Balmoori, Jeremiah J. Morrissey, Ying Maggie Chen, Limei Tian, Srikanth Singamaneni   +10 more
wiley   +1 more source

Predictive Biomarkers of Antibody-Drug Conjugate Efficacy for Solid Tumors: Current Challenges and the Potential Role of Quantitative Proteomics. [PDF]

Clin Cancer Res
McNamee NJ, Liu J, Poulos RC, Aref AT, Reddel RR.   +4 more
europepmc   +1 more source

Anisotropic Masked Mycobacterium Potentiates Amplified Antitumor Trained Immunity via Spleen Targeting and Myelopoiesis Conversion

Advanced Materials, EarlyView.
An engineered Trojan Mycobacterium, developed via a “peeling‐off and masking‐up” strategy, functions as a powerful splenic myelopoiesis converter. This spleen‐targeted nanomedicine induces trained immunity to reprogram immunosuppressive myeloid reservoirs into antitumoral effectors.
Jin‐Ho Choi, Sang Nam Lee, Jang Hun Heo, Soyoung Park, Sei Hyun Park, Yong Taik Lim   +5 more
wiley   +1 more source

Targeted Delivery of a Potent STING Agonist Payload via an Antibody-Drug Conjugate Drives Robust Antitumor Activity in Preclinical Models. [PDF]

Mol Cancer Ther
Gruber DR, Cummins EJ, Zeng W, Ulrich M, Smith K, Long M, Spahr K, Higgins S, Hinricher K, Langalia A, Krumm K, Olson DJ, Grogan B, Mazahreh R, Gupta P, Burke PJ, Smith A, Senter PD, Gardai SJ, Hill AG, Gray EE.   +20 more
europepmc   +1 more source

Transient Cytoskeletal Anisotropy Encodes Short‐Term Mechanical Memory in Glioblastoma Cells

Advanced Materials, EarlyView.
The same mechanical deformation can produce distinct cytoskeletal states depending on loading history. Experiments and constitutive modeling reveal that transient actin–vimentin anisotropy stores mechanical information and governs short‐term mechanical memory in glioblastoma cells.
Clara Gomez‐Cruz, Matthieu Gelin, Lucas Pradeau‐Phélut, Arrate Muñoz‐Barrutia, Sandrine Etienne‐Manneville, Daniel Garcia‐Gonzalez   +5 more
wiley   +1 more source

Preclinical Pharmacokinetic, Pharmacodynamic, and Safety Profile of OBI-992: A Novel TROP2-Targeted Antibody-Drug Conjugate. [PDF]

Mol Cancer Ther
Shia CS, Wen SN, Hsu RY, Tu JS, Chang HW, Weng HC, Yang JJ, Chiang MF, Tsao YH, Lu CH, Chen YH, Wu YC, Chen YC, Li WF, Huang TY, Lai MT.   +15 more
europepmc   +1 more source

EGFR- and HER3-targeted bispecific antibody-drug conjugate demonstrates antitumor activity in metastatic castration-resistant prostate cancer. [PDF]

J Clin Invest
Fang B, Li X, Lu Y, Ma W, Gan H, Zhang T, Liu Q, Wang B, Wang Z, Zhu Y, Zhu H, Xiao S, Bian X, Wei G, Ye D, Zhu Y.   +15 more
europepmc   +1 more source

Correction: Harnessing ExDNA for precision Exatecan delivery in cancer: a novel antibody-drug conjugate approach. [PDF]

Mol Cancer
Ianniello Z, Lu H, Quijano E, Colón-Ríos DA, Rackear M, Bommireddy V, Ludwig DL, Shen Z, Glazer PM.   +8 more
europepmc   +1 more source